Reuters	reuter	Reuters
-	-	-
Two	two	Two
key	key	key
U	u	U
.	.	.
S	s	S
.	.	.
congressional	congression	congressional
committee	committe	committee
members	member	member
on	on	on
Friday	friday	Friday
called	call	called
for	for	for
an	an	an
investigation	investig	investigation
into	into	into
whether	whether	whether
Mylan	mylan	Mylan
NV	nv	NV
,	,	,
under	under	under
fire	fire	fire
for	for	for
raising	rais	raising
the	the	the
price	price	price
of	of	of
its	it	it
EpiPen	epipen	EpiPen
device	devic	device
,	,	,
overcharged	overcharg	overcharged
the	the	the
government	govern	government
s	s	s
low	low	low
-income	-incom	-income
healthcare	healthcar	healthcare
program	program	program
for	for	for
the	the	the
allergy	allergi	allergy
treatment	treatment	treatment
.	.	.
In	in	In
a	a	a
letter	letter	letter
to	to	to
the	the	the
secretary	secretari	secretary
of	of	of
the	the	the
Department	depart	Department
of	of	of
Health	health	Health
and	and	and
Human	human	Human
Services	servic	Services
,	,	,
Senator	senat	Senator
Ron	ron	Ron
Wyden	wyden	Wyden
and	and	and
Representative	repres	Representative
Frank	frank	Frank
Pallone	pallon	Pallone
,	,	,
both	both	both
Democrats	democrat	Democrats
,	,	,
seek	seek	seek
clarification	clarif	clarification
of	of	of
whether	whether	whether
EpiPen	epipen	EpiPen
was	was	wa
classified	classifi	classified
as	as	a
a	a	a
generic	generic	generic
,	,	,
non	non	non
-innovator	-innov	-innovator
drug	drug	drug
,	,	,
or	or	or
a	a	a
brand	brand	brand
-name	-name	-name
drug	drug	drug
by	by	by
the	the	the
Medicaid	medicaid	Medicaid
program	program	program
.	.	.
Under	under	Under
current	current	current
law	law	law
,	,	,
branded	brand	branded
drugs	drug	drug
,	,	,
and	and	and
generic	generic	generic
drugs	drug	drug
available	avail	available
from	from	from
a	a	a
single	singl	single
source	sourc	source
,	,	,
are	are	are
required	requir	required
to	to	to
pay	pay	pay
a	a	a
rebate	rebat	rebate
amount	amount	amount
of	of	of
at	at	at
least	least	least
23	23	23
.	.	.
1	1	1
percent	percent	percent
of	of	of
the	the	the
average	averag	average
manufacturer	manufactur	manufacturer
price	price	price
.	.	.
Generic	generic	Generic
drugs	drug	drug
are	are	are
subject	subject	subject
to	to	to
a	a	a
much	much	much
lower	lower	lower
13	13	13
percent	percent	percent
rebate	rebat	rebate
.	.	.
Mylan	mylan	Mylan
,	,	,
in	in	in
an	an	an
emailed	email	emailed
statement	statement	statement
,	,	,
said	said	said
it	it	it
has	has	ha
complied	compli	complied
with	with	with
all	all	all
laws	law	law
and	and	and
regulations	regul	regulation
regarding	regard	regarding
Medicaid	medicaid	Medicaid
rebates	rebat	rebate
,	,	,
and	and	and
intends	intend	intends
to	to	to
file	file	file
with	with	with
regulators	regul	regulator
,	,	,
by	by	by
next	next	next
April	april	April
as	as	a
required	requir	required
under	under	under
new	new	new
guidelines	guidelin	guideline
,	,	,
for	for	for
EpiPen	epipen	EpiPen
to	to	to
be	be	be
classified	classifi	classified
as	as	a
a	a	a
non	non	non
-innovator	-innov	-innovator
product	product	product
.	.	.
The	the	The
device	devic	device
jabs	jab	jab
a	a	a
dose	dose	dose
of	of	of
the	the	the
drug	drug	drug
epinephrine	epinephrin	epinephrine
into	into	into
the	the	the
thigh	thigh	thigh
to	to	to
counter	counter	counter
dangerous	danger	dangerous
allergic	allerg	allergic
reactions	reaction	reaction
such	such	such
as	as	a
to	to	to
peanuts	peanut	peanut
,	,	,
food	food	food
allergies	allergi	allergy
and	and	and
bee	bee	bee
stings	sting	sting
.	.	.
Mylan	mylan	Mylan
,	,	,
whose	whose	whose
tax	tax	tax
address	address	address
is	is	is
in	in	in
the	the	the
Netherlands	netherland	Netherlands
but	but	but
which	which	which
has	has	ha
corporate	corpor	corporate
headquarters	headquart	headquarters
in	in	in
Canonsburg	canonsburg	Canonsburg
,	,	,
Pennsylvania	pennsylvania	Pennsylvania
,	,	,
has	has	ha
raised	rais	raised
the	the	the
U	u	U
.	.	.
S	s	S
.	.	.
price	price	price
of	of	of
EpiPen	epipen	EpiPen
from	from	from
less	less	le
than	than	than
100	100	100
when	when	when
it	it	it
acquired	acquir	acquired
the	the	the
product	product	product
in	in	in
2007	2007	2007
to	to	to
more	more	more
than	than	than
600	600	600
.	.	.
Amid	amid	Amid
an	an	an
outcry	outcri	outcry
by	by	by
parents	parent	parent
,	,	,
consumer	consum	consumer
groups	group	group
and	and	and
U	u	U
.	.	.
S	s	S
.	.	.
politicians	politician	politician
,	,	,
the	the	the
company	compani	company
said	said	said
on	on	on
Monday	monday	Monday
it	it	it
will	will	will
soon	soon	soon
launch	launch	launch
the	the	the
first	first	first
generic	generic	generic
version	version	version
of	of	of
the	the	the
device	devic	device
for	for	for
300	300	300
,	,	,
half	half	half
the	the	the
list	list	list
price	price	price
of	of	of
its	it	it
branded	brand	branded
product	product	product
.	.	.
Wyden	wyden	Wyden
,	,	,
ranking	rank	ranking
member	member	member
of	of	of
the	the	the
Senate	senat	Senate
Finance	financ	Finance
Committee	committe	Committee
,	,	,
and	and	and
Pallone	pallon	Pallone
,	,	,
ranking	rank	ranking
member	member	member
of	of	of
the	the	the
House	hous	House
Energy	energi	Energy
Commerce	commerc	Commerce
Committee	committe	Committee
,	,	,
said	said	said
in	in	in
the	the	the
letter	letter	letter
on	on	on
Friday	friday	Friday
It	it	It
has	has	ha
recently	recent	recently
come	come	come
to	to	to
our	our	our
attention	attent	attention
that	that	that
Mylan	mylan	Mylan
has	has	ha
classified	classifi	classified
EpiPen	epipen	EpiPen
as	as	a
a	a	a
generic	generic	generic
drug	drug	drug
under	under	under
the	the	the
Medicaid	medicaid	Medicaid
rebate	rebat	rebate
program	program	program
,	,	,
even	even	even
though	though	though
it	it	it
is	is	is
considered	consid	considered
a	a	a
new	new	new
drug	drug	drug
by	by	by
the	the	the
Food	food	Food
and	and	and
Drug	drug	Drug
Administration	administr	Administration
.	.	.
Shares	share	Shares
of	of	of
Mylan	mylan	Mylan
,	,	,
which	which	which
fell	fell	fell
4	4	4
.	.	.
7	7	7
percent	percent	percent
to	to	to
close	close	close
at	at	at
39	39	39
.	.	.
97	97	97
on	on	on
Friday	friday	Friday
,	,	,
have	have	have
dropped	drop	dropped
19	19	19
percent	percent	percent
since	sinc	since
mid	mid	mid
-August	-august	-August
.	.	.
